CAJ | 학술논문

目的探讨Egr-IFNγ基因治疗联合放射性核素125I-脱氧尿嘧啶核苷治疗方案在荷1422肝癌细胞小鼠体内抑瘤效应及机制.方法小鼠肿瘤局部注射脂质体包裹的质粒,注射后48 h,肿瘤局部注射370 kBq 125I-UdR.观察各组小鼠治疗后不同时间肿瘤生长率;治疗后第3天,检测肿瘤胞浆蛋白中IFNγ的表达和脾脏CTL细胞毒活性.结果基因-放射核素治疗后第6～15天,pcDNAEgr-IFNγ+125I-UdR组肿瘤生长率明显低于对照组、125I-UdR组及pcDNAEgr-1+125I-UdR组;基因.放射性核素治疗后第3天,pcDNAEgr-IFNγ+125I-UdR组肿瘤胞浆蛋白中可检测到IFNγ的表达,其余组肿瘤胞浆蛋白中未检测到IFNγ的表达;PcDNAEgr-IFNγ+125I-UdR组小鼠脾脏CTL细胞毒活性明显高于其余组(P<0.01).结论 pcDNAEgr-IFNγ基因治疗联合放射性核素125I-UdR治疗抑瘤效应明显优于单纯125I-UdR放射性核素治疗.
목적 탐토Egr-IFNγ기인치료연합방사성핵소125I-탈양뇨밀정핵감치료방안재하1422간암세포소서체내억류효응급궤제.방법 소서종류국부주사지질체포과적질립,주사후48 h,종류국부주사370 kBq 125I-UdR.관찰각조소서치료후불동시간종류생장솔;치료후제3천,검측종류포장단백중IFNγ적표체화비장CTL세포독활성.결과 기인-방사핵소치료후제6～15천,pcDNAEgr-IFNγ+125I-UdR조종류생장솔명현저우대조조、125I-UdR조급pcDNAEgr-1+125I-UdR조;기인.방사성핵소치료후제3천,pcDNAEgr-IFNγ+125I-UdR조종류포장단백중가검측도IFNγ적표체,기여조종류포장단백중미검측도IFNγ적표체;PcDNAEgr-IFNγ+125I-UdR조소서비장CTL세포독활성명현고우기여조(P<0.01).결론 pcDNAEgr-IFNγ기인치료연합방사성핵소125I-UdR치료억류효응명현우우단순125I-UdR방사성핵소치료.
Objective To explore the anti-tumor effects of Egr-IFNγ gene therapy combined with 125I-UdR radionuclide therapy in mice bearing H22 hepatocarcinoma and its mechanism. Methods The recombinant plasmid pcDNAEgr-IFNγ mixed with liposome was injected into tumor. 48 h later, 370 kBq 125I-UdR was injected into tumor. The tumor growth rates at different times were observed. After 3 d gene-radionuclide therapy, the concentration of IFNγ in cytoplasm of H22 cells and cytotoxic activities of splenic CTL of the mice in different groups were examined. Results The tumor growth rates of pcDNAEgr-IFNγ +125 I-UdR group were obviously lower than those of control group, 125I-UdR group and pcDNAEgr-1 +125I-UdR group 6-15 d after gene-radionuclide therapy. IFNγ protein was found in cytoplasm of H22 cells in PcDNAEgr-1FNγ+125I-UdR group after 3 d gene-radionuclide therapy. Cytotoxic activity of splenic CTL in pcDNAEgr-IFN7 + 125I-UdR group was significantly higher than that in the other groups (P<0.01). Conclusions The anti-tumor effects in vivo of pcDNAEgr-IFNγ gene therapy combined with 125I-UdR radionuclide therapy are better than those of 125I-UdR therapy.